This compound is primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a key linker component, connecting the target protein-binding moiety to the E3 ubiquitin ligase-recruiting moiety. The inclusion of the PEG3 spacer enhances solubility and flexibility, optimizing the molecule's ability to facilitate the formation of the ternary complex necessary for ubiquitination and subsequent proteasomal degradation of the target protein. Its application is significant in drug discovery, especially for targeting undruggable proteins or those resistant to traditional inhibitors, offering potential therapeutic strategies for cancer, neurodegenerative diseases, and other conditions driven by aberrant protein activity.